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Abstract 
Background: Over the last decade, Ethiopia adopted different strategies of prevention of mother to child transmis-
sion of HIV (PMTCT). Prior to implementation of Option A in 2011, there was no provision of prophylaxis for PMTCT. 
With ‘Option A’, PMTCT interventions relied on maternal CD4 count. In early 2013, ‘‘Option B+’’ has been started; with 
this option, antiretroviral therapy is started and continued for life to any HIV positive pregnant mother irrespective 
of CD4 count with an enhanced treatment for the baby. Though there are a number of studies which evaluated the 
effectiveness of PMTCT interventions, the current study assessed the real-world effectiveness of PMTCT options in a 
setting where there is limitation of resources.
Objective: This study tried to address three questions: what proportion of babies tested by DNA-PCR are HIV infected 
in the first 2 months of life? How does the type of PMTCT intervention affect presence of HIV infection at this age? 
What are the factors affecting HIV transmission, after controlling for type of PMCT-HIV intervention?
Methods: We assessed records of 624 registered HIV exposed infants and 412 mothers who were delivered at Bish-
oftu Hospital from May 2006 to August 2014. Presence of HIV infection at 6–8 weeks of age was assessed from the 
records. Maternal and infant risk factors for infection at this age were analyzed. Data were collected using standard 
data abstraction format and were analyzed using SPSS version 20.
Results: Among all the infants who were delivered at the hospital during the study period, 624/936 (66.7 %) had 
undergone early infant diagnosis at 6–8 weeks. Twenty-seven (4.3 %) were positive for HIV DNA PCR at the age of 
6–8 weeks. None of the infants who received ‘‘Option B+’’ had a positive HIV DNA PCR result. HIV infection rate was 
highest among those who took either no prophylaxis or single dose Nevirapine (11.5 and 11.1 % respectively). Those 
who took single dose Nevirapine and Zidovudine had HIV positivity rate of 3.9 %. Many of the covariates which were 
shown to be predictors on bivariate analysis were found not to be independent predictors on multivariate analysis.
Conclusion: PMTCT ‘’Option B+’’ resulted in zero HIV infection rates among the included infants. There was a high 
loss to follow up rate at 6–8 weeks of age. The authors recommend that a better strategy of linkage to care and treat-
ment should be devised for HIV exposed infants.
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Background
In 2011, United Nations General Assembly Special Ses-
sion (UNGASS) placed a clear emphasis on the effect 
of HIV/AIDS on maternal and child health. The final 
declaration of commitment from the assembly stated is 
to reduce the number of children newly infected with 
HIV by 90 % by 2015 [1]. Mother-to-child transmission 
(MTCT) of HIV accounts for 14 % of all new HIV infec-
tions worldwide, and may occur during pregnancy, labor 
and delivery or breastfeeding. In the absence of preven-
tion, rates of MTCT are estimated to be 25–45 % [2, 3]. 
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In 2012, according to the Ethiopian Health and Nutrition 
Research Institute, MTCT rates were 15 and 30 % with-
out and with breast feeding respectively [4]. Timely ini-
tiation of PMTCT interventions dramatically improved 
the natural history of perinatal infections [5, 6].
Ethiopia is among countries working to achieve the 
goal set by UNAIDS in 2011, the Joint United Nations 
Program on HIV/AIDS; a global call for the elimination 
of MTCT by 2015 [2, 7, 8]. Over the past couple of years, 
Ethiopia adopted the different strategies of PMTCT. It 
has been implementing the 1  year accelerated PMTCT 
plan for ‘Option A’ since December 2011. ‘Option-A’ 
treatment or prophylaxis is dependent on CD4 count. It 
requires a variety of drugs across the continuum which 
creates complexity in patient management. Since early 
2013, Ethiopia launched the ‘‘Option B+’’ PMTCT 
approach which proposes the same triple antiretroviral 
drugs to all HIV-infected pregnant women, beginning in 
the antenatal clinic setting, but also continuing this ther-
apy for all these women for life without need for an initial 
CD4 test and a 6 week Nevirapine therapy for the infant 
[9].
While many countries still practice the WHO 2010 
guidelines with either Option A or B, the PMTCT and 
cost effectiveness of Option B+  has been increasingly 
reported [10–13]. Gopalappa et  al. described the cost 
effectiveness of Option B+  comparing it with Option 
A and B. It was the most cost-effective strategy costing 
between $6000 and $23 ,000 per infection averted com-
pared with Option A. Option B+  averted more child 
infections compared with Option B and costed less 
than Option B. Considering adult sexual transmissions 
averted, Option B+  was found to cost less and averted 
more infections than both Options A or B [11]. Though 
many of the studies indicated that Option B+ is an effec-
tive PMTCT approach, its real-world performance might 
be different because of differences in patient socio-demo-
graphics and the availability of resources for patient fol-
low up care.
In the current study, we hypothesize that the real-world 
effectiveness of Option B+ PMTCT in preventing MTCT 
of HIV in the first few months of life is higher than the 
previous approach of Option A. The current study was 
done to assess the real world effectiveness of Option 
B+ in preventing MTCT in a setting where resources are 
meagre and prevalence of HIV is high as compared to the 
developed world. Due to lack of resources for early infant 
diagnosis, in the Ethiopian context, many HIV exposed 
infants do not undergo a second DNA PCR for HIV test 
after the first 6–8 weeks test. We assessed the rate of pos-
itivity of the first DNA PCR for HIV done at 6–8 weeks 
of age based on the existing national early infant diagno-
sis guidelines of HIV infection; and the effectiveness of 
different strategies for PMTCT over the past 8  years at 
one of the largest hospitals in Ethiopia. We also assessed 
the associated factors of DNA-PCR positivity for HIV 
among HIV-exposed infants at Bishoftu hospital.
Methods
Data collection was conducted at Bishoftu hospital from 
November to March 2014. Bishoftu city has a total popu-
lation of about 128,400 in 2013 [8]. Bishoftu hospital is 
one of the oldest health institutions in Ethiopia; it serves 
as referral center for 10 health centers with a catchment 
of over 1 million people. Apart from other services, the 
hospital is providing HIV chronic care including PMTCT 
services since 2004. In the area, the adult prevalence rate 
of HIV is estimated at 2.4  % and the incidence rate is 
0.29  %. The urban prevalence rate is higher and is esti-
mated at 7.7 %, while the rural prevalence rate is 0.9 %. 
The prevalence rate is 1.7  % for males and 2.6  % for 
females. With 90,000 HIV-positive pregnant women, 
there are an estimated 14,000 HIV-positive births and a 
total of 28,000 AIDS death annually [14].
A retrospective record review was done among infants 
and their mothers from the HIV exposed infant regis-
ters of the Hospital. All records of HIV-exposed infants 
registered between May 2006 and August 2014 at Bish-
oftu hospital were included in the study. All records 
of exposed infants and their mothers were included. 
Excluded were those infants with no DNA PCR result at 
6–8 weeks, missing infant/mother charts and those who 
had DNA PCR result after 8 weeks since they were very 
few in number.
There is a separate HIV exposed infant registration 
form. The registers are both paper and computer based. 
The PMTCT nurse fills the HIV exposed infant form 
which is distributed by the Ministry of Health and the 
data clerk enters individual patient data to a computer 
based database. The registration started in 2001 at three 
hospitals in the country [15]. From infants’ registers, 
mothers’ record numbers were documented and hence, 
allowed for retrieval of respective maternal records of 
each infant. The electronic medical record of the mother 
and the corresponding infants were cross-checked for 
the availability of their data and were linked with infant 
records in order to confirm real mother infant pair.
Information on demographic characteristics and 
uptake of different components of the PMTCT package 
were obtained from HIV exposed infant follow-up charts, 
HIV care/ART follow up charts and intake forms, and 
antenatal patient charts using data abstraction forms.
To ensure quality of data, the abstraction tool was pre 
tested and all were checked for completeness before data 
entry. Data abstraction was made by a team of trained 
nurse data collectors. Supervision during data collection 
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and data entry were conducted. Quality of collected data 
was continuously checked by the principal investiga-
tor and random checks by one of the co-authors. Errors 
and consistency checking procedures for the data were 
controlled during analysis. Data were checked, cleaned, 
coded and entered in EPI info version 3.5.1 and were 
exported to SPSS version 20 for further analysis.
Independent variables were tested for predicting rate 
of positivity of DAN PCR for HIV using bivariate logis-
tic regression. Then all variables having p ≤  0.05 in the 
bivariate analysis were further entered into multivari-
ate logistic regression model and variables which had 
p < 0.05 were retained as independent predictors of posi-
tivity of DNA PCR at 6–8 weeks.
In the current study, MTCT of HIV was considered 
as transmission of HIV from HIV positive mother to 
her child during pregnancy, childbirth and early breast-
feeding. PMTCT intervention refers to the use of ART 
or ARV drugs in mother and infant to reduce MTCT of 
HIV. “Loss to follow up” was defined in the current study 
as not showing up for early infant diagnosis or other HEI 
care and treatment after the initial registration. A mother 
was considered as taking the various options based on 
the information given in Table  1 [16]. Ethiopia adopted 
Option A in 2011 and then directly changed to Option 
B+ in 2013. Hence, there was no experience with Option 
B [15].
Since the age at first DNA PCR test was not directly 
recorded, it was calculated from the records using the 
date of birth column and the date when sample for DNA 
PCR testing was collected.
Ethical consideration
Ethical clearance was obtained from Institutional Review 
Board (IRB) IRB of University of Gondar. Permission let-
ter was obtained from the management Committee of the 
Bishoftu Hospital (Ref.BH-219/2007 issued 15/5/2007) 
prior to data collection. Since the study utilizes routinely 
collected, aggregated program data at the hospital, con-
fidentiality of patient information was ensured as the 
names or identification number of study participants was 
not included in the data collection format.
Results
A total of 936 HIV exposed infants were registered 
at Bishoftu hospital during the study period. Among 
these, records of 624 exposed infants and 412 mothers 
were included for the study. One hundred ninety-nine 
(22.2  %) were lost to follow up care and treatment; the 
rest 113/936 (12.1 %) were excluded because they didn’t 
have DNA-PCR result for HIV at the age of 6–8 weeks or 
had incomplete records.
Among the infants included in the analysis, 323/624 
(51.8  %) were male. Included infants were 6  weeks, 
574/624 (92  %); 7  weeks, 8/624 (1.3  %); and 8  weeks, 
42/624 (6.7 %) of age at the time of DNA PCR for HIV 
test. The majority, 295 (47.5  %) of the mothers were on 
antiretroviral therapy during pregnancy while 50/624 
(8  %) were on single dose Zidovudine for PMTCT pur-
pose. Mothers who have not received any PMTCT ARVs 
were 123/624 (14.9 %) during ANC and 95/624 (15.2 %) 
during labor. Most of the babies, 525/624 (84.1 %) were 
delivered at health institutions.
The majority, 494/624 (79.2 %) were on exclusive breast 
feeding whereas, 91/624 (14.6 %) and 29/624 (4.7 %) were 
on exclusive replacement and mixed feeding respectively. 
Based on the country’s guidelines at the time of enrol-
ment, 305/624 (48.9 %) of the infants were on the former 
WHO recommendation of single dose Nevirapine or 
single dose Nevirapine with Zidovudine. The remaining 
179/624 (28.7) and 12/624 (1.8 %) were on Nevirapine for 
6 weeks and Nevirapine for greater than 6 weeks respec-
tively. No prophylaxis was given to 90 (14.4 %) infants of 
which 42/90 (46.67 %) were born at home. Unfortunately, 
Table 1 The PMTCT options and interventions for the mother and baby
Treatment (for CD4 
count <350 cells/mm3)
Prophylaxis (for CD4  
count >350 cells/mm3)
Infant receives
Option A Triple ARVs starting as 
soon as diagnosed, 
continued for life
Antepartum: AZT starting as early as 14 weeks  
gestation Intrapartum: at onset of labour, single-
dose NVP and first dose of AZT/3TC
Postpartum: daily AZT/3TC through 7 days post-
partum
Daily NVP from birth until 1 week after cessation of all 
breastfeeding; or, if not breastfeeding or if mother is 
on treatment, through age 4–6 weeks
Option B Triple ARVs starting as 
soon as diagnosed, 
continued for life
Triple ARVs starting as early as 14 weeks gestation 
and continued intrapartum andthrough childbirth 
if not breastfeeding or until 1 week after cessation 
of all breastfeeding
Daily NVP or AZT from birththrough age 4–6 weeks 
regardless of infant feeding method
Option B+ Triple ARVs starting as 
soon as diagnosed, 
continued for life
Triple ARVs starting as soon as diagnosed,  
continued for life
Daily NVP or AZT from birth through age 4–6 weeks 
regardless of infant feeding method
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48/90 (53.33  %) of those infants who didn’t receive any 
prophylaxis were born at health facility (Table  2). The 
mean CD4 counts of mothers of babies who were positive 
for HIV DNA-PCR and those who were not at 6–8 weeks 
were comparable (415.00 (SD  =  331.47)/mm3 and 418 
(SD  =  239.09); p  >  0.05 respectively). All HIV exposed 
infants were initiated on Co-trimoxazole at enrollment.
Among the included infants, 27/624 (4.3 %) were posi-
tive for HIV-DNA PCR at the age of 6–8 weeks. Among 
191 infants who took Nevirapine for 6  weeks or more, 
none of them had a positive HIV DNA PCR result. The 
highest positive result rate was observed for those who 
took either no prophylaxis or single dose Nevirapine 
(11.5 and 11.1 % respectively). And those who took com-
bination of single dose Nevirapine and Zidovudine had a 
positivity rate of 3.9 %.
Various factors were identified as predictors of posi-
tivity of HIV DNA-PCR on the bivariate analysis. Being 
born at home (Crude OR, 3.26 95  % CI 1.24–8.53; 
p =  0.016), maternal CD4 count during pregnancy less 
than 100 cells/mm3 (Crude OR, 5.68 95 % CI 1.15–28.05; 
p = 0.033), absence of any PMTCT interventions for the 
mother (Crude OR, 6.10 95 % CI 2.45–15.17; p < 0.0001), 
absence of antenatal care follow up (Crude OR, 5.54 95 % 
CI 2.27–13.52; p  <  0.0001), and mother not enrolled in 
HIV care and treatment during pregnancy (Crude OR, 
4.32 95 % CI 1.66–11.24; p = 0.003) were associated with 
increased probability of HIV infection at 6–8  weeks. 
However, none of these variables were found to be inde-
pendent predictors of positivity using multivariate logis-
tic regression (Table 3).
Discussion
Our findings showed that the infection rate at 6–8 weeks 
of DNA-PCR for HIV was at 4.3 %. This figure is small as 
compared to the study at St. Luke hospital, Gondar Uni-
versity Referral hospital, and Tanzania [17–19]. Infants 
who took PMTCT "Option B+" were all negative for HIV 
at 6–8 weeks while those who didn’t take any prophylaxis 
or those who took single dose Nevirapine had the highest 
infection rate. The findings underscore the importance 
of enhancing PMTCT interventions for both the mother 
and the infant at the earliest possible.
The current findings showed that there is a significantly 
high loss to follow up. Among all the enrolled infants, 199 
(22.2 %) were lost to follow up. This figure is lower than 
39.4 and 40.4  % lost to follow up rates by studies at St. 
Luke hospital and Mc Cord hospital of KwaZulu-Natal, 
South Africa respectively [18, 20]. The differences could 
be possibly from the time at measurement of loss to fol-
low up, which in our case was at 6–8 weeks of age. Since 
Table 2 Characteristics of  mothers and  infants included 
in the study during the specified study period (2006–2014) 
at the PMTCT/ART center of Bishoftu Hospital
a Antenatal care
b Zidovudine
c Highly active antiretroviral therapy
d Nevirapine
Variable Frequency (N) Percentage (%)
Sex
Male 323 51.8
Female 301 48.2
Place of birth
Health facility 525 84.1
Home 55 8.8
Unknown 44 7.1
Type of infant feeding
Exclusive breast feeding 494 79.2
Exclusive complementary feeding 91 14.6
Mixed feeding 29 4.7
Weaned of breast feeding 2 0.3
Mothers CD4 during ANCa
Less than 100 15 2.4
101–300 73 11.7
301–500 124 19.9
More than 500 182 29.2
Mother clinical stage during ANC
WHO stage 1 224 35.9
WHO stage 2 104 16.7
WHO stage 3 100 16
WHO stage 4 9 1.4
Undocumented 187 70
PMTCT intervention in the mother
None/unknown 279 44.7
Yes 345 55.3
Type of PMTCT intervention (mother)
AZTb only 50 8
HAARTc 295 47.3
None 105 16.8
Missing 174 27.9
Infant PMTCT intervention
Sd NVPd 26 4.2
Sd NVP + AZT 279 44.7
NVP for 6 weeks 179 28.7
NVP >6 weeks 12 1.9
None 90 14.4
Missing 38 6.1
Mother ANC
Yes 86 13.8
No 388 62.2
Missing 150 24
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the current study assessed loss to follow up at 6–8 weeks 
of age, it does not account for those infants who would be 
lost to follow up after the first DNA PCR and those who 
were excluded from the study. Hence, the current find-
ings could be an underestimate of the overall problem of 
loss to follow up. The findings underscore for the need 
for better strategies to track and link HIV exposed infants 
to care and treatment throughout the time of exposure 
(during pregnancy, labor and delivery and breastfeeding).
One of the PMTCT interventions is starting mothers 
on prophylaxis as early as possible. In the current study, 
123 (14.9 %) mothers during ANC and 95 (15.2 %) moth-
ers during labor have not received any PMTCT interven-
tion. Higher missed opportunities were reported by a 
group from St. Luke hospital; southwest Ethiopia in 2014 
[18]. The differences could reflect the recent improve-
ments in ANC coverage and provision of PMTCT inter-
ventions since our study addressed both the recent and 
Table 3 Associated factors with DNA PCR positivity at 6–8 weeks of age
a X2 test was used
b Single dose
c Treatment
Variable DNA-PCR result p value Crude OR (95 % CI) Adjusted OR (95 % CI)
Positive (%) Negative (%)
Sex 0.992
Male 14 (4.3) 309 (95.7) 0.992 1.00 (0.46–2.17)
Female 13 (4.3) 288 (95.7) Ref
Place of birth 0.016
Health facility 19 (3.6) 506 (96.4) Ref Ref
Home 6 (10.9) 49 (89.1) 3.26 (1.24–8.53) 3.10 (0.53–18.24)
Type of feeding 0.104
Exclusive BF 16 (3.2) 478 (96.8) Ref
Exclusive RF 6 (6.5) 85 (93.5) 2.11 (0.80–5.54)
Mixed feeding 3 (6.9) 28 (93.1) 0.66 (0.16–2.81)
Infant PMTCT 0.000a –
Sdb NVP or none 13 (11.2) 103 (88.8)
Sd NVP + AZT 11 (3.9) 268 (96.1)
Sd NVP ≥6 weeks 0 (0) 191 (100)
Mother CD4 during pregnancy 0.033
<100/mm3 3 (17.6) 14 (82.4) 5.68 (1.15–28.05) 4.50 (0.71–28.56)
100–500/mm3 3 (1.3) 236 (98.7) 0.34 (0.08–1.53) 0.26 (0.05–1.33)
>500/mm3 4 (3.6) 106 (96.4) Ref Ref
Mother WHO stage 0.344
WHO stage 1 7 (3.3) 204 (96.7) Ref
WHO stage 2 2 (2.1) 91 (97.9) 0.64 (0.13–3.14)
WHO stage 3/4 6 (6) 93 (94) 1.88 (0.62–5.75)
Mother any PMTCT 0.000
No 13 (12.7) 89 (87.3) 6.10 (2.45–15.17) 3.80 (0.68–21.09)
Yes 8 (2.3) 334 (97.7) Ref Ref
Type of PMTCT (mother) 0.402
AZT only 2 (4) 48 (96) 2.01 (0.39–10.24)
HAART 6 (2) 289 (98) Ref
Antenatal care follow up 0.000
No 11 (12.8) 75 (87.2) 5.54 (2.27–13.52) 4.05 (0.25–65.75)
Yes 10 (2.6) 378 (97.4) Ref Ref
Mother care and treatment 0.003
Enrolled in care and Rxc 14 (3.3) 406 (96.7) Ref –
Not enrolled 7 (13) 47 (87) 4.32 (1.66–11.24)
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old data. It can be taken as a clue for meeting the goal 
set by the Ethiopia FMOH to provide PMTCT prophy-
laxis for 85 % of eligible pregnant women by end of 2015 
[21]. Findings from Johannesburg, South Africa showed a 
lower missed intra partum PMTCT intervention oppor-
tunity of 7.36 %; indicating the better health care in the 
setting [6]. Also, 90 (14.4 %) of the infants did not get any 
PMTCT intervention. This figure is lower when com-
pared to a similar study done in southwest Ethiopia 163 
(38.3 %) and in Gondar University hospital in 2013 both 
of which have similar HIV transmission dynamics to the 
current setting [18]; but slightly higher than Johannes-
burg study which was 12 (5.2 %) [6].
In the current study, possibly because of the relatively 
small number of babies who had a positive DNA PCR 
result and the higher ANC coverage, in contrast to the 
studies in St. Luke hospital and Gondar University Hos-
pital which have a similar HIV transmission dynamics, 
ANC follow up, lack of PMTCT intervention and mater-
nal WHO clinical stage were not associated with infant 
HIV infection at 6–8 weeks of age [17, 18].
In order to avoid the increased incidence of diarrhea, 
pneumonia, and death observed with replacement feed-
ing, WHO recommends breastfeeding duration for 
2  years for HIV exposed infants [22]. However, the risk 
of HIV infection among infants was found to be higher. 
Our findings showed that infants on breast feeding and 
complementary feeding were found to be three times 
more likely to have a DNA PCR result positive as com-
pared to those on exclusive breast feeding. The difference 
in infection rate was reported to be higher in other simi-
larly done studies [17, 18].
The limitations of the current study include its retro-
spective nature posing problems of incomplete record-
ings. Moreover, the data used in this study were not 
originally collected for research purposes and therefore 
the quality of the data might not be good. Since this is a 
record review, we cannot confidently confirm the accu-
racy of the information reported and documented by the 
clinicians. The transmission rate reported in the study is 
probably an underestimation of the actual MTCT since 
follow up data including transmission during breast feed-
ing is not reported in the current study. The abstraction 
forms lacked information on year of enrolment and could 
not give more information on the number of infants 
enrolled in each specific year during the record review 
period.
Conclusions
PMTCT ‘‘Option B+’’ resulted in zero infection rates 
among the included infants. There was a high loss to fol-
low up rate even at 6–8  weeks of age. The authors rec-
ommend that a better strategy of linkage to care and 
treatment of HIV exposed infants to care and treatment 
should be devised.
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